Despite new mechanisms of action and updated clinical trial data for treatment strategies in pulmonary hypertension, HCP awareness is low within the community. Learn about new trial results, the impact of the heart structure, and how fixed-dose combination therapy will be adopted into practice.
The Next Generation of Treatment for Patients With PH
4
episodes
1.00 program credits1h 01m
Details
Presenters
Comments
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Richard Channick, MD
Director, Pulmonary Vascular Disease Program
UCLA Medical Center
Los Angeles, CADr. Channick has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Aria CV, Janssen
Consulting Fees: Janssen, Bayer, Third Pole, Respira, Gossamer, Liquidia, United TherapeuticsVallerie McLaughlin, MD
Professor, Internal Medicine
University of Michigan
Ann Arbor, MIDr. McLaughlin has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months.
Research: Aerovate, Altavant, Gossamer Bio, Janssen, Merck, SoniVie
Consulting fees: Aerami, Aerovate, Altavant, Bayer, Caremark, CorVista, Gossamer Bio, Janssen, Merck, United TherapeuticsIoana Preston, MD
Associate Professor of Medicine
Tufts University School of Medicine
Boston, MADr. Preston has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Actelion/Janssen, Acceleron/Merck, Keros, Liquidia, Respira, United Therapeutics
Consulting fees: Actelion/Janssen, Acceleron/Merck, Aerovate, Gossamer, Keros, Liquidia, Respira, United TherapeuticsReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Susan Diaz has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Prerna Poojary has nothing to disclose.
- Leticia Samaras has nothing to disclose.
- Katie Sheridan has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss how new agents and trial results within the pulmonary hypertension (PH) community will impact care moving forward
- Review how clinical endpoints are relative to outcome measures in PH
- Provide insights into how to mitigate adverse events while maximizing therapy for patients with PH
Target Audience
This activity is designed to meet the educational needs of cardiologists and pulmonologists, as well as physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with pulmonary hypertension.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until July 31, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.10 CEUs of pharmacy contact hours. The Universal Activity Number for this program is JA0006235-0000-24-082-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, and Merck Sharp & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
